Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Investor Presentation (May 2013)
27 slides from Niagen Bioscience's investor presentation, May 29, 2013
Slide 1: ChromaDex Investor Presentation May 2013
C ) ChromaDex May 2013 Investor Presentation
Slide 2: Disclaimers
Disclaimers 2 Safe Harbor This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
Slide 3: The ChromaDex Mission
i - . : : “ «The ChromaDexe Mission 3 “i % CY 4 1 To lead research, regulatory and quality control in the natural products industry, through the continued growth of the legacy standards & analytical services business To gain market intelligence and enable the identification of 2 Ingredient Technolog
Slide 4: ChromaDex's Unique Business Model
vom * | ~ rs ; , ‘Established Customers’ FDA sds Cornell University 1 ses) ‘© Dartmouth Fens Van. YT Ra Cargill PEPSICO KRAFT. ESTEE LAUDER @ HERBALIFE ChromaDex®’s Unique Business Model | 4 « Established and growing brand « Thousands of customers worldwide Reference \ ' ndards Research Materials An
Slide 5: Advantage Comes from the Legacy Business
¥ ‘a, This Advantage Comes from the Legacy Business, a « “ss@ Revenue-generating Platform with 14 Years of Expertise in Ca y the Natural Products Industry Natural product fine chemicals Analytical & chemistry-based services ® Used for QA & R&D ® Testing of products for @ $3.5M revenue in 2012 identi
Slide 6: Legacy Standards & Analytical Services Business Positioned for Growth
y 4 '* The Legacy Standards & Analytical Services Business is 6 “4i=4 Positioned for Growth | ‘ Cid Increased consumer demand — natural products industry expected to reach $243B by 20151 t Increased R&D by global blue-chip players — e.g. Pepsi Global Nutrition Group, Nestle Health Sciences t Increas
Slide 7: ChromaDex's Unique Model Gives First-mover Advantages
V ™, ChromaDexe’s Unique Model Gives it Protected, wees ix First-mover Advantages in Acquiring Ingredient Technologies ia °C Insight to Consumer “ Access to Research... “ 9 i / / % Markets... \ { / \ \ /~ Over 250 University & Research / \, Over 1500 Industry Customers, Institution customers i a i /
Slide 8: Discover, Acquire, Develop and Commercialize Ingredient Technologies
Discover or Discover novel, early-stage Ingredient Technologies, leveraging intelligence gained from activities of the legacy business ChromaDex® Discovers, Acquires, & Develops Early-stage Proprietary Ingredient Technologies and Commercializes them! 8 in Multi-billion-dollar Markets Acquire these D
Slide 9: Commercialization Opportunities in Multi-billion-dollar Markets
¥ ‘™ ChromaDexe’s Ingredient Technologies have | eo Commercialization Opportunities in Multi-billion-dollar Markets ! Commercialization Opportunity Ingredient Ingredient Technology Size($) CAGR Sales Licensing Dietary Supplements 30B Th | Functional Food & Beverage 40B 8% | Animal Health 20B 5% Cosm
Slide 10: Ingredient Technology Acquisition Precedents
OO MARTEK O life enriched < fey < Z < 10 wellness through innovation -=) NEPTUNE Q Ganecien Labs Patented vegetarian omega-3 ingredient Fish Oil omega-3 Krill Oil omega-3 Probiotic technology 10 Acquired by DSM for $1.08B in 2010 Acquired by DSM for $550M in July 2012 Market cap $150-$250M Acquired
Slide 11: ChromaDex Ingredient Technology Portfolio
yee ChromaDex® Ingredient Technology Portfolio Monetization 11 Clinical Dietary Food & pler®Pure Pas. PURENERGY ~~ NIAGEN. ProC3G. Cransdin-3-qhucoside Ganthopure Supply Safety De Animal Health Skin Care Pharma Pterostilbene Y Y g) A ae 1% study complete Pterostilbene- caffeine cocrystal Y 4, G) O O
Slide 12: pTeroPure Development Timeline
—EEEE 2003: Collaborates with USDA to provide reference standards for R&D (legacy business activity) 2003-2012: Obtains exclusive access to USDA research & begins collaborating on pterostilbene development 2009: Partners with manufacturer to achieve commercial- scale production of pterostilbene; lic
Slide 13: pTeroPure Pterostilbene Brand
@ Blueberries Contain the Powerful Antioxidant Pterostilbene; ChromaDex® has Developed and is Monetizing its |P-backed & Clinically-studied Brand, pTeroPure® | 13 pleréPure pTeroPure® is ChromaDex-branded pterostilbene ® Pterostilbene is a phytoalexin (plant defense system) found naturally in bluebe
Slide 14: pTeroPure Phase 2/3 Clinical Study
pTeroPure® was Evaluated in a Phase 2/3 Clinical Study laa Which Showed Statistically Significant Results for Lowering Blood Pressure pleréPure Clinical trial completed at the University of Mississippi » Double-blind, randomized, placebo-controlled, IRB-reviewed » 80 patients, 4 arms. Eight-week dur
Slide 15: Monetization of pTeroPure Underway
Monetization of pTeroPure®is Underway as Channel Expansion and Uptake Continues Dietary Supplements Gunctional Rood, Animal Health Pharmaceuticals Beverage MI ATIATL IAA Dodo Organic PLAINUIVI 16 ® Organic Blueberry @ Premium equine @ Physician channel Granola bar products ® Organic Date bar Pursuin
Slide 16: Sale of Retail Brand BluScience to NeutriSci International
ChromaDex® Completed Sale of Retail Brand BluScience® to NeutriSci International; Foundation Ingredient is pTeroPure® 16 4 a 5 ‘ s° BluSciencé p; aScience» BluScience BluScience ploscionce§é 9 9 9 9\ 2 fewre eoNepatanpae EE oPurs Cena a In exchange for selling to NeutriSci: ® Paid $6.2m made of: - $
Slide 17: PURENERGY Combination of pTeroPure and Caffeine
PURENERGY™ is a Unique Combination of pTeroPure® and Caffeine, Which is Poised to Revolutionize the Energy | 17 Beverage Market , PURENERGY NZ Overview @ By cocrystallizing caffeine with pTeroPure ® pterostilbene, caffeine’s energy boost is sustained over a significantly extended period of time — 6-
Slide 18: Regulatory Scrutiny of Caffeinated Energy Products
Caffeinated Energy Products have been Coming Under Increased Regulatory and Political Scrutiny Regarding the | 18 Possible Risks of Consuming High Amounts of Caffeine A PLURENERGY Sq al ® March 2012 —a Chicago City Alderman proposed banning energy drinks with at least 180 milligrams of caffeine. ® O
Slide 19: NIAGEN Nicotinamide Riboside Launch
a Pg (7) MIAGEN™ ChromaDex Launched in May 2013 and is the 1% and 49 ®@ oniy Commercially Available Brand of Nicotinamide Riboside NIAGEN. Overview « Nicotinamide Riboside (NR) — The “Miracle Molecule” - is a compound naturally found in milk and shown to boost nicotinamide adenine dinucleotide (NAD)
Slide 20: Commercialization of NIAGEN
pre (3) Commercialization of NAGEN™ 20 — NIAGEN. « NIAGEN™ may have tremendous appeal to the approximately 150 million Americans who are obese or over weight as well as the 75 million aging baby boomers in the U.S. — both of which are actively seeking new dietary supplement solutions for obesity or
Slide 21: ProC3G Anthocyanin
(4) ProC3G™ - Anthocyanin 1 a ProC3G. Oanthopure Cyanidin-3-glucoside : Overview i @ Anthocyanins are compounds responsible for the deep purple color in H berries, flowers, black rice and other botanicals H @ Specific anthocyanins have been studied more extensively and have Bases ivr shown promising
Slide 22: Patent Status by Ingredient
22 @ Issued patent Patent O Patent pending Status Partner Pterostilbene plersPure Nicotinamide Riboside NIAGEN. Anthocyanins ProC3G. ganth Gyanidin3-giucoside
Slide 23: ChromaDex Highlights
Discover Acquire ChromaDexe Highlights 23 Develop \ Focused Expertise ChromaDex’s legacy standards & analytical services business continues to grow at a steady rate as it has over the last 14 years. Its expertise in the natural products industry gives the company a unique platform of market intellig
Slide 24: ChromaDex Management Team
ChromaDexe Management Team 24 Frank Jaksch Co-Founder, CEO, Director ® Founded ChromaDex in 1999 ® Intl idiari at Ph ® Expertise in analytical chemistry, product development ® Recognized industry expert, most recently appearing on Dateline NBC’s Hansen Files regarding quality testing in the natural
Slide 25: Shareholder Summary
Shareholder Summary 25 Percent Shareholder Number of Shares Ginette Dr. Phillip Frost 15,252,937 15.08% Opko Health, Inc (NYSE:OPK) 4,833,333 1.81% Frank L. Jaksch Jr. (Founder, CEO, Director) 7,993,320 7.90% Other Directors and Officers 17,731,494 17.53% Total Insider Ownership 25,724,814 25.43% SU
Slide 26: ChromaDex At a Glance
ChromaDexe At a Glance «@ Founded 1999 by CEO, Frank Jaksch @ Headquarters: Irvine, CA @ Analytical Laboratory: Boulder, CO - Acquired in April 2003 from NaPro BioTherapeutics a: ® Regulatory Consulting: Rockville, MD Irvine, CA - Acquired Spherix Consulting in December 2012 @ Employees: Approximate
Slide 27: Contact Information
Contact Information ChromaDex, Inc. 10005 Muirlands Blvd., Suite G Irvine, CA 92618 Phone: +1-949-419-0288 Fax: +1-949-419-0294 www.chromadex.com Investor Relations 27 Bob Prag, President The Del Mar Consulting Group, Inc. Phone: 858.794.9500 bprag@delmarconsulting.com Scott Wilfong, President Alex